Modern Vaccines Adjuvants & Delivery Systems

12-14 September 2017, Crowne Plaza Hotel, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Tuesday 12th September 2017

08.00 Onwards
Registration

08.55-09.00
Welcome & Opening Remarks

SESSION 1:
OPENING PLENARY

Moderator: Chris Fox
(IDRI, Seattle, Washington, USA)

09.00-09.30
‘Adjuvants: Where are we now?’
Derek O’Hagan
(GSK, Rockville, Maryland, USA)

09.30-10.00
‘Inducible adjuvant mediated by multiple, but specific pathways’
Ken Ishii
(NIBIOHN/Osaka University, Osaka, Japan)

10.00-10.30
‘Making vaccines on demand: iVAX and Ancer’
Brian Roberts
(EpiVax Inc., Providence, Rhode Island, USA)

10.30-11.00
Coffee Break & Poster Set-Up

SESSION 2:
PLENARY II

Moderator: Derek O’Hagan
(GSK, Rockville, Maryland, USA)

11.00-11.30
‘Predictive modification of adjuvant activity’
Chris Fox
(IDRI, Seattle, Washington, USA)

11.30-12.00
‘Polyanhydride nanovaccines: A new platform technology for emerging infectious diseases’
Adel M. Talaat
(University of Wisconsin, Madison, Wisconsin, USA)

12.00-12.30
‘A new generation of a versatile adjuvant A that is delivering, targeting and immune modulating’
Bror Morein, Caroline Fossum and Saideh Berenjian
(Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden)

12.30-12.50
‘TRANSVAC2 – European Vaccine Research and Development Infrastructure’
Stefan Jungbluth and Odile Leroy
(European Vaccine Initiative, Heidelberg, Germany) and TRANSVAC2 consortium partners

12.50-14.00
Lunch Break & Posters

SESSION 3:
MUCOSAL

Moderator: Anna-Karin Maltais
(Eurocine Vaccines AB, Solna, Sweden)

14.00-14.20
‘Mucosal Vaccines & Adjuvants Overview’
Ali Harandi
(University of Gothenburg, Gothenburg, Sweden)

14.20-14.40
‘Mucosal Immunity is what’s missing, Dude!! Building the Right wall to protect against respiratory and sexually transmitted diseases’
Ali Fattom, Vira Bitko and Doug Smith
(NanoBio Corp., Ann Arbor, Michigan, USA)

14.40-15.00
‘The oral adjuvant α-Galactosylceramide activates intestinal B cells via an IFN-γ dependent mechanism’
Stephanie Longet1, Christopher Davitt1, Joshua Tobias2, Jan Holmgren2 and Ed C. Lavelle1
(1 Trinity College Dublin, Dublin, Ireland; 2 University of Gothenburg, Gothenburg, Sweden)

15.00-15.20
‘Oral immunization for the prevention of norovirus infection’
Sean Tucker
(Vaxart Inc., South San Francisco, California, USA)

15.20-15.40
‘Adjuvants targeting STING and the NLRP3 inflammasome to enhance cellular immunity’
Edward Lavelle
(Trinity College Dublin, Dublin, Ireland)

15.40-16.00
‘Clinical development of an inactivated nasal influenza vaccine’
Anna-Karin Maltais
(Eurocine Vaccines AB, Solna, Sweden)

16.00-16.30
Tea Break & Posters

SESSION 4:
DESIGN & MODELS

Moderator: Heather Davis
(Seqiris, Maidenhead, Berkshire, UK)

16.30-17.00
‘Targeted delivery in rational vaccine design’
Dennis Christensen
(Statens Serum Institut, Copenhagen, Denmark)

17.00-17.30
‘NHP models for vaccines, adjuvants and delivery systems’
Edmond J. Remarque
(Biomedical Primate Research Centre, Rijswijk, The Netherlands)

17.30-18.00
‘Self-adjuvanted protein nanoparticles as a platform for vaccine design’
Caroline Kulangara, Sara M. Paulillo, Senthil K. Raman and Peter Burkhard
(Alpha-O Peptides AG, Riehen, Switzerland)

18.00-19.00
MVADS 2017 Welcome Drinks Reception & Poster Session

 

MVADS 2017 Delegates

Login details will be supplied after you have registered for the event.


MVADS 2017 Sponsors

  • Bill and Melinda Gates Foundation
  • BIA Separations
  • IDRI
  • NatureGeneTherapy.com
  • Mymetics
  • Inovio
  • iZon Science
  • Vaxart
  • Matrivax
  • Eurocine Vaccines
  • CureVac
  • Novavax
  • DNAvaccine.com
  • Seppic
  • Aldevron
  • Precision Vaccines Program
  • VisMederi
  • EVI
  • BioAster
  • Mucosis
  • Brenntag
  • Janssen
  • Pfizer
  • National Institute of Allergy and Infectious Diseases
  • Univac
  • BPRC
  • Sanofi Pasteur

MVADS 2017 Downloads

MVADS 2017 Leaflet

MVADS 2017 Mailing List

Name
E-mail Address
What is 3+2-1?